Mutations in SMARCA4 have been shown to co-exist with KRAS mutations but are mutually exclusive from common targetable non-small cell lung carcinoma (NSCLC) oncogenes, including EGFR, ALK, MET, ROS-1, and RET [1,3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.